Apellis Pharmaceuticals, Inc.
APLS
Rangering i aksjer
#3321
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Aksjekurs
$41.03
Sist synkronisert: 2026-05-15
Markedsverdi
$5.25B
Endring (1 dag)
0.00%
Endring (1 år)
67.33%
Land
US
Handel Apellis Pharmaceuticals, Inc. (APLS)
Kategori
Healthcare
EPS for Apellis Pharmaceuticals, Inc. (APLS)
EPS per March 2026 TTM: $1.06
Ifølge de siste økonomiske rapportene og aksjekursen til Apellis Pharmaceuticals, Inc. er selskapets nåværende EPS (TTM) $1.06. Ved slutten av 2023 hadde selskapet en EPS på $-4.45, en nedgang sammenlignet med EPS-en i 2022 som var $-6.15.
EPS-historikk for Apellis Pharmaceuticals, Inc. fra 2013 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $1.06 | -166.25% |
| 2024 | $-1.60 | -64.04% |
| 2023 | $-4.45 | -27.64% |
| 2022 | $-6.15 | -30.43% |
| 2021 | $-8.84 | 92.59% |
| 2020 | $-4.59 | -7.83% |
| 2019 | $-4.98 | 112.82% |
| 2018 | $-2.34 | 57.05% |
| 2017 | $-1.49 | -0.67% |
| 2016 | $-1.50 | -41.63% |
| 2015 | $-2.57 | 328.33% |
| 2014 | $-0.60 | -30.23% |
| 2013 | $-0.86 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | 1,533.96% |
US
|
|
| $-7.98 | -852.83% |
US
|
|
| $-5.29 | -599.06% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 2,516.98% |
NL
|
